Maxicef (Cefixime) is an antibiotic applied across therapeutic domains involving susceptible bacterial infections, providing targeted support for the clearance of pathogens and relief from associated acute symptoms. Cefixime is commonly used across a range of bacterial illnesses.

The medication is primarily used for managing conditions characterized by periods of heightened symptoms, including tonsillitis, pharyngitis, acute otitis media, uncomplicated urinary tract infections (UTIs), and acute exacerbations of chronic bronchitis. It is also relevant in conditions presenting with systemic or localized discomfort, such as Typhoid Fever and certain sexually transmitted infections.

“This type of therapy is considered relevant when symptoms related to physical discomfort and inflammation create noticeable functional strain.”

The medication is applied in addressing symptom clusters that may become intense or disruptive, such as sore throat, earache, or painful urination. Its use supports the patient during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Symptomatic Support Focus
Key Benefit Focus	Helps manage symptoms that interfere with daily comfort
Clinical Context	Relevant in acute or unstable symptom patterns
Patient Benefit	Supports the easing of the overall symptom burden

Regulatory References

1. NIH DailyMed official label for Cefixime

Maxicef (Cefixime) eligibility is strictly defined by regulatory documents based on patient history, age, and organ function.

Contraindicated Populations

Use of Cefixime is contraindicated in patients with a known allergy or hypersensitivity to the drug, to other cephalosporin antibiotics, or to any beta-lactam antibiotic (e.g., penicillin) if the reaction was severe.

Age-Related and Conditional Eligibility

Population Group	Regulatory Eligibility Status
Infants under 6 months	Safety and efficacy have not been established.
Pediatric patients ge 6 months	Use is established.
Renal Impairment	Dose adjustment is required for patients with markedly impaired renal function (creatinine clearance < 60 mL/min or < 20 mL/min, depending on regulatory label).
Pregnancy	Use only if clearly needed (Category B).
Lactation	Temporary discontinuation of nursing should be considered, as it is unknown if Cefixime is excreted in human milk.
History of Colitis/Penicillin Allergy	Use with caution due to documented risks of beta-lactam cross-allergenicity or gastrointestinal effects.

The official eligibility profile mandates absolute exclusion for known hypersensitivity and establishes clear age minimums. For otherwise eligible adults and children, it imposes mandatory restrictions based on renal status, ensuring appropriate use.

Interactions with other medicines and products

Interaction Scope

Category	Entity/Statement
Medicinal product categories with documented interactions	Anticoagulants (Vitamin K antagonists)
Specific interacting medicines (if explicitly listed)	Warfarin, Carbamazepine, Nifedipine
Mechanistic basis of interactions (only if stated in label)	Not specified as a restriction based on CYP enzyme or transporter mechanisms.
Timing-based interaction rules (if applicable)	No mandatory time-separation rules are specified for co-administered medicines.
Population-specific interaction notes (if applicable)	No population-unique interaction risks are specified in the official labels.
Interaction-related restrictions	No formal contraindications based solely on interaction mechanisms are listed.

Interaction Classifications (High-Level)

Category	Description
Interaction severity classification (as defined in official documents)	Clinically Significant: Documented effects on coagulation and drug exposure.
Regulatory basis	FDA Prescribing Information and European Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents)	Food: Administration of the oral suspension with food is constrained by a documented increase in drug exposure.

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Warfarin and other anticoagulants is associated with an officially documented increased Prothrombin Time (PT).
• The concurrent use of Carbamazepine has been reported to result in elevated plasma levels of that medicine.
• Concomitant intake with Nifedipine is officially documented to increase Cefixime bioavailability (increasing Cmax and AUC).
• Administration of the Cefixime oral suspension with food results in a documented increase in Cefixime exposure.

Connection to the overall interaction profile (3 sentences): The regulatory documents define the product's interaction structure through two domains: pharmacodynamic effects involving anticoagulation and pharmacokinetic alterations that result in modified drug exposure for both co-administered substances and Cefixime itself. The official profile includes a specific administration constraint tied to food intake, which is documented to increase the exposure of the oral suspension form. These statements detail the formally documented interaction patterns without providing clinical interpretation or guidance.

Covalent Inhibition of Bacterial Cell Wall Assembly

Cefixime operates by functioning as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs), key enzymes located in the bacterial cell membrane. The drug's molecular structure binds tightly and permanently to the PBP active site, covalently deactivating the enzyme. This molecular block halts the process of peptidoglycan cross-linking, which is the final, essential step in building and maintaining the structural integrity of the bacterial cell wall.

Catastrophic Cell Lysis (Bactericidal Action)

The structural failure caused by PBP inhibition leaves the bacterial cell wall weak and unable to withstand the high osmotic pressure exerted from within the cell. This defect leads to a mechanistic cascade where the cell membrane ruptures (lysis), resulting in the rapid, physical destruction of the susceptible organism. This direct, destructive process defines Cefixime’s bactericidal effect profile.

Third-Generation Stability and Mechanistic Constraints

As a third-generation cephalosporin, Cefixime’s mechanism exhibits chemical stability against many common bacterial beta-lactamase enzymes, which maintains the molecule's integrity for interaction with the PBP target. However, the mechanism is constrained by advanced resistance factors, notably certain Extended-Spectrum beta-Lactamases (ESBLs), which can inactivate the drug, and by bacterial modification of the PBP targets themselves.

Cefixime is administered orally in formulations including capsules, film-coated tablets, and a powder for oral suspension. The standard adult regimen requires a total daily dose of 400 mg, which can be taken as a single dose once daily or divided into 200 mg taken every 12 hours. Solid dosage forms may be administered without regard to food.

The required duration of treatment typically ranges from 7 to 14 days, with a minimum course of 10 days necessary for infections caused by Streptococcus pyogenes. For pediatric patients 6 months of age and older, the dose is calculated based on 8 mg/kg/day of the oral suspension. The suspension form requires professional reconstitution before administration. Tablets and capsules are not substituted for the oral suspension when treating otitis media.

Dosing is adjusted based on specific patient factors. For adults with severe renal impairment (creatinine clearance < 20 mL/min), the daily dose should not exceed 200 mg once daily. If a dose is missed, it should be taken as soon as possible, or skipped if near the next scheduled time, and the regular schedule should be resumed.

Usage Principle	Instruction
Route	Oral (by mouth)
Adult Standard Dose	400 mg/day (once daily or 200 mg BID)
Pediatric Dose	8 mg/kg/day (for ge 6 months)
Renal Impairment	le 200 mg once daily (for CrCl < 20 mL/min)
Duration	Typically 7–14 days; ge 10 days for certain pathogens
Food Relation	Without regard to food

Research Evidence / Overview of Studies for Maxicef (Cefixime)

---

Evidence for Use in Acute Throat and Ear Infections (Tonsillitis, Pharyngitis, and Otitis Media)

Research related to Maxicef (Cefixime) in the context of acute throat and ear infections includes short-term Randomized Controlled Trials (RCTs). These studies were designed to examine the medicine in both adults and pediatric patients. The outcomes monitored primarily centered on bacteriological eradication—which is the measurement of bacterial clearance—and the rate of clinical response, an assessment of symptom change. Findings from comparative trials have described patterns of clinical response measured alongside those of established comparative treatments. What remains uncertain is the long-term functional outcome following treatment, as most studies focus on immediate or short-term results.

---

Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

For uncomplicated urinary tract infections, studies have primarily consisted of comparative trials designed to evaluate Cefixime. The primary goals were to measure clinical cure (resolution of symptoms like painful urination) and bacteriological eradication (the study's predefined measure of bacterial clearance). The populations included were mainly adult women presenting with acute symptoms. Research has also explored the evaluation of short-course regimens. A key limitation is that evidence largely focuses on uncomplicated cases, meaning there is limited information for individuals with more complex patterns.

---

Evidence in Special Populations (Children and Specific Infection Sites)

Evidence relating to pediatric patients is primarily focused for acute otitis media and throat infections, where dedicated RCTs have been conducted. These studies specifically monitored children to understand how symptoms evolved in this age group. In the context of certain sexually transmitted infections, research has explored the medicine’s use in adult patients by measuring clinical response based on specific anatomical sites. Findings were mixed, with some research highlighting changes measured during the study period reporting lower response measurements for pharyngeal infections. Research is ongoing to provide context related to drug concentration and absorption.

Key Studies & References

1. Label: CEFIXIME capsule - DailyMed (Official FDA Regulatory Information)

Common questions about Maxicef (Cefixime) (FAQ)

Q: Can I drink alcohol while taking this medication?

A: Official regulatory information specifies whether caution is required regarding the use of alcohol with this medicine. It indicates if the use of alcohol is contraindicated (should not be taken) or if specific caution is necessary due to the potential for increased adverse effects, such as central nervous system depression.

Q: Does this medication cause drowsiness or affect my ability to drive?

A: Regulatory documents indicate that this medication may cause certain side effects, such as dizziness or somnolence (drowsiness). If such effects occur, caution should be taken when driving or operating machinery, as the ability to perform these tasks may be affected.

Q: What information is available regarding the use of this medication during pregnancy or while breastfeeding?

A: Official labeling contains specific data and recommendations regarding the use of Maxicef during pregnancy and lactation. This information often includes a risk classification or specific details for healthcare providers to consider, based on clinical studies and approved regulatory data.

Q: How should I store this medication?

A: The official drug labeling specifies the exact storage conditions required to maintain the quality and effectiveness of the product. This includes the required temperature range and any instructions to protect the medicine from light or moisture.

Q: What is the primary condition this medication is approved to treat?

A: Maxicef (Cefixime) is officially indicated for the treatment of specific bacterial infections, as defined and approved in the regulatory labeling. The approved uses are listed in the 'Indications and Usage' section of the official product information.

Q: What should I do if I miss a dose?

A: The official patient information provided by regulatory authorities contains general guidance regarding missed doses. This typically addresses whether a dose should be taken immediately upon realizing it was missed or if it should be skipped to resume the regular dosing schedule.

Q: What does the official labeling say about the use of this medication in children who are 2 years old?

A: Regulatory information on pediatric use details the minimum age for which Maxicef is approved or if it is specifically not recommended for children below a certain age. This reflects the criteria set out in the product's official labeling.

Q: What are the common side effects of this medicine?

A: The official document lists common, less common, and serious side effects observed in clinical trials. These may include mild effects such as nausea, headache, or dizziness. A comprehensive list of potential reactions is detailed in the Adverse Reactions section of the labeling.

Maxicef (Cefixime) must be stored and discarded according to specific instructions to maintain its integrity and ensure public safety, as defined by regulatory labeling.

Official Storage and Stability Rules

Item	Requirement per Regulatory Labeling
Storage Temperature	Solid forms and the powder must be kept at Controlled Room Temperature (20 C to 25 C).
Suspension Storage	The reconstituted oral suspension may be stored at room temperature or under refrigeration, but must not be frozen.
Stability Limit	Any unused portion of the reconstituted suspension must be discarded after 14 days.
Handling & Packaging	Store in the tightly closed original container, protected from excessive heat, moisture, and direct light.
Child Safety	Keep this medicine strictly out of the sight and reach of children and pets.

Official Disposal Instructions

Unused or expired Maxicef should be disposed of primarily through an authorized medicine take-back program. It is a formal requirement that the medication must not be flushed down a toilet or sink, as Cefixime is not on the government's flush list. As an alternative to take-back, the medication should be mixed with an undesirable substance, sealed, and placed in the household trash.